Adam M. Kase, MD

Genitourinary Oncologist at Mayo Clinic Florida. Proud father of 3. All tweets and comments reflect my own opinion.

[FDA Oncology @FDAOncology]

FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors. https://t.co/PrklmlcNRg

#OCENewsBurst

[Adam M. Kase, MD @AdamKase]

Join me at 2024 IRONMAN 70.3 Chattanooga on May 19, 2024! https://t.co/RXFfT99LaJ

[Adam M. Kase, MD @AdamKase]

@BradMcG04 @maughanonc @WeickhardtOnc @MichaelPalliola Let’s do it..I think my legs could use some more punishment

[Adam M. Kase, MD @AdamKase]

No better way to see San Fran than a morning run..tried to keep up with the GU onc runners @BradMcG04 @maughanonc @WeickhardtOnc @MichaelPalliola..now time to hear about the latest and greatest at #GU2023

[Adam M. Kase, MD @AdamKase]

Well said..

[Ravi A Madan M.D. @Dr_RaviMadan]

3 Strategies To Lead #Clinical #Research With Moral Integrity

“While data integrity is of utmost importance in clinical research, moral integrity is of greater importance.”

—Ravi Madan, MD, senior clinician, ⁦@theNCI⁩ ⁦⁦@NCIResearchCtr⁩
https://t.co/dDnjlcrcwU

[Adam M. Kase, MD @AdamKase]

Triple therapy now an option!

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Breaking news: @US_FDA approves darolutamide (Nubeqa) for metastatic castration sensitive #prostatecancer in combination with docetaxel based on the results of ph3 Arasens trial👇 @PCF_Science @OncoAlert @urotoday https://t.co/hsJ005pHjE

[Adam M. Kase, MD @AdamKase]

Check this out…find those with TMB 10+ ..ICI better than taxanes. ICIs vs Chemotherapy by TMB in Metastatic Castration-Resistant Prostate Cancer https://t.co/VIMJgGIvhx via @JAMANetworkOpen part of @JAMANetwork @DrWinstonTan1 @RDroncaDr

[Ravi A Madan M.D. @Dr_RaviMadan]

While #BCR & #mCSPC #ProstateCancer exist on a Continuum, it is important to note that #ADT combo studies for mCSPC have all required positive findings on conventional imaging (CT & Tc99)

Thus no data actually supports ADT combinations based on PET findings alone

[Adam M. Kase, MD @AdamKase]

@RManochakian Wow, exciting news to see pCR and prolonged EFS. Will look forward to OS data when mature.

[Rami Manochakian MD, FASCO Cancer Education @RManochakian]

Thank you @ConquerCancerFd & @ASCO for these Merit Awards to support #Trainees to participate & contribute in important scientific meetings such as #GU22.
Proud of Dr @AdamKase #HemOnc chief fellow @MayoCancerCare, Florida to be one of the recipients.
#KnowledgeConquersCancer

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Just in: Propel trial of PARP inhibitor Olaparib + abiraterone in UNSELECTED pts in 1st line mCRPC #ProstateCancer meets its primary end point:rPFS Results bode well for ongoing trials with Enza+ Talazoparib and Abi+ Niraparib👇 https://t.co/ogHfMVd7ZV @OncoAlert @urotoday

[Aakash Desai, MD, MPH, FASCO @ADesaiMD]

The #vaccine #race is on! Which is great for #medicine and the world! Obviously the scientific community awaits the detailed results for analysis but this is good news- here’s an update from @Brief_19 on how these 2 vaccines compare! @OncoAlert @COVID19nCCC @reverendofdoubt

[Adam M. Kase, MD @AdamKase]

@BernardAFox @gulleyj1 @theNCI @sitcancer @NCIDirector @NIHDirector Well done. Congrats.

[Adam M. Kase, MD @AdamKase]

Time to investigate targeted combinations in prostate cancer. Let’s take advantage of these alterations. #GUoncology #prostatecancer #individualizedmedicine

Novel Therapeutic Strategies for CDK4/6 Inhibitors in Metastatic Castr | OTT @DovePress https://t.co/6HZHzktnbl

[Toni Choueiri, MD @DrChoueiri]

JUST Now, and a wow! Adjuvant nivolumab improves DFS as for high-Risk, Muscle-Invasive Urothelial Carcinoma (CheckMate-274). Big news for bladder cancer patients. Congrats @MattGalsky &colleagues! @OncoAlert . Melanoma, GEJ/E #ESMO20 and now UC for #nivo
https://t.co/KG5MOrHCXw

[European Urology @EUplatinum]

Apalutamide and Overall Survival in Prostate Cancer
@scserendipity1 @OudardStephane @ProfHadaschik @Dolmos77
https://t.co/lp4acRcFcy

[Akash Patnaik, MD, PhD, MMSc @AkashPatnaik7]

Happy to share our manuscript, demonstrating that co-targeting of PARP and PI3K signaling activates c-GAS/STING pathway within tumor-associated macrophages, thereby driving T cell recruitment/activation and tumor clearance in c-myc-driven prostate cancers.
https://t.co/zGPyZjMzy8

[@gulleyj1 @gulleyj1]

A long awaited study by Dr. Graff and colleagues. A phase II single-arm study of pembrolizumab with enzalutamide in mCRPC progressing on enzalutamide alone. Still waiting for the magic combination with #Immunotherapy for #ProstateCancer. https://t.co/IjJ1ggp50R

[The ASCO Post @ASCOPost]

Overall Survival With the Addition of ADT or Brachytherapy Boost to External-Beam Radiotherapy in Patients With Localized Prostate Cancer https://t.co/fbHqIYS0Mb #pcsm #oncology #cancer #radonc

[Adam M. Kase, MD @AdamKase]

Prostate cancer management heading in the right direction with targeted therapy.

[FDA Oncology @FDAOncology]

May 19: FDA approved olaparib (LYNPARZA, AstraZeneca) for deleterious/suspected deleterious germline or somatic HRR gene-mutated metastatic castration-resistant prostate cancer that has progressed following treatment with enzalutamide or abiraterone
#pcsm
https://t.co/faiRYdKkZe